Hillsdale Investment Management Inc. Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Hillsdale Investment Management Inc. grew its position in shares of Pfizer Inc. (NYSE:PFE) by 762.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 46,095 shares of the biopharmaceutical company’s stock after buying an additional 40,750 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Pfizer were worth $1,223,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on PFE shares. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.1 %

PFE opened at $26.20 on Monday. The company has a market capitalization of $148.61 billion, a PE ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm’s 50 day simple moving average is $26.17 and its two-hundred day simple moving average is $27.04. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the firm earned $0.10 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.